相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blockade of Glutathione Metabolism in IDH1-Mutated Glioma
Xiaoying Tang et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
Yang Liu et al.
CANCERS (2020)
Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid
Yang Liu et al.
CLINICAL CANCER RESEARCH (2020)
Targeting IDH1-Mutated Malignancies with NRF2 Blockade
Yang Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Triptolide induces oxidative damage in NRK-52E cells through facilitating Nrf2 degradation by ubiquitination via the GSK-3β/Fyn pathway
Ji Pan et al.
TOXICOLOGY IN VITRO (2019)
Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs
Pelin Telkoparan-Akillilar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Potential Applications of NRF2 Inhibitors in Cancer Therapy
Emiliano Panieri et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP
Casey J. Moure et al.
MOLECULAR CANCER RESEARCH (2019)
Brusatol, an NRF2 inhibitor for future cancer therapeutic
Sabrina J. Cai et al.
CELL AND BIOSCIENCE (2019)
Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity
Jiayu Zhu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2018)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (vol 18, pg 2780, 2017)
Farshad Farshidfar et al.
CELL REPORTS (2017)
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Yanxin Lu et al.
CANCER RESEARCH (2017)
An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy
Jiayu Zhu et al.
FREE RADICAL BIOLOGY AND MEDICINE (2016)
Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion
Kensuke Tateishi et al.
CANCER CELL (2015)
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Remco J. Molenaar et al.
CANCER RESEARCH (2015)
Triptolide suppresses proliferation, hypoxia-inducible factor-1α and c-Myc expression in pancreatic cancer cells
Xiaoling Ding et al.
MOLECULAR MEDICINE REPORTS (2015)
Mutational landscape and clonal architecture in grade II and III gliomas
Hiromichi Suzuki et al.
NATURE GENETICS (2015)
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Andrew Kernytsky et al.
BLOOD (2015)
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Jinlong Shi et al.
TUMOR BIOLOGY (2015)
The emerging role of the Nrf2-Keap1 signaling pathway in cancer
Melba C. Jaramillo et al.
GENES & DEVELOPMENT (2013)
Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1α and Nrf2
Feili Chen et al.
PHARMACOGENOMICS (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
Alexandra Borodovsky et al.
ONCOTARGET (2013)
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Peppi Koivunen et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Histone Demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Protein Nuclear Stabilization
Chibawanye I. Ene et al.
PLOS ONE (2012)
β-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas
Chunzhang Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Dongmei Ren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Tao Jiang et al.
CANCER RESEARCH (2010)
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Meghan J. Seltzer et al.
CANCER RESEARCH (2010)
Nrf2 and Keap1 Abnormalities in Non-Small Cell Lung Carcinoma and Association with Clinicopathologic Features
Luisa M. Solis et al.
CLINICAL CANCER RESEARCH (2010)
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin
Yoo Ri Kim et al.
JOURNAL OF PATHOLOGY (2010)
Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
Ping Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues
Rui Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy
Anju Singh et al.
CANCER RESEARCH (2008)
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Xiao-Jun Wang et al.
CARCINOGENESIS (2008)
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer
Tatsuhiro Shibata et al.
GASTROENTEROLOGY (2008)
Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation
Andy Y. Shih et al.
JOURNAL OF NEUROSCIENCE (2006)
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer
Anju Singh et al.
PLOS MEDICINE (2006)
Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation
M Kobayashi et al.
ANTIOXIDANTS & REDOX SIGNALING (2005)
Nrf2-Keap1 defines a physiologically important stress response mechanism
H Motohashi et al.
TRENDS IN MOLECULAR MEDICINE (2004)
D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats
A Latini et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2003)
Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-κB activation
KY Lee et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2002)
分享论文
